| Browse All

Adagene Inc. (ADAG)

Healthcare | Biotechnology | Suzhou, China | NasdaqGM
3.80 USD -0.09 (-2.314%) ⇩ (April 21, 2026, 4 p.m. EDT)

Short-term:☆☆☆☆☆Long-term:★☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | April 18, 2026, 10:22 p.m. EDT

Despite strong clinical headlines and a narrowed forward P/E suggesting potential stabilization, the short-term momentum is critically bearish with a model predicting -1.47% downside over the next 45 days. The massive 44.6% expansion in short interest indicates intense skepticism among market participants, and the recent price action shows a failed breakout attempt after hitting $4.61, leaving the stock vulnerable to volatility below recent lows.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoETS ✓0.321263
AutoTheta0.322077
MSTL0.329389
AutoARIMA0.346954

Forecast horizon: 45 days | Selected: AutoETS

Forecast Reliability
Score 47%
H-stat 5.66
Ljung-Box p 0.000
Jarque-Bera p 0.286
Excess Kurtosis -1.15
Attribute Value
Sector Healthcare
Debt to Equity Ratio 12.068
Revenue per Share 0.163
Market Cap 251,075,856
Forward P/E -7.31
Beta 0.59
Profit Margins -229.56%
Website https://www.adagene.com

Info Dump

Attribute Value
52 Week Change 1.5675676
Address1 Building C14
Address2 4th Floor No. 218, Xinghu Street Suzhou Industrial Park
All Time High 31.83
All Time Low 0.9
Ask 3.8
Ask Size 1
Average Analyst Rating 1.3 - Strong Buy
Average Daily Volume10 Day 440,630
Average Daily Volume3 Month 278,101
Average Volume 278,101
Average Volume10Days 440,630
Beta 0.587
Bid 3.8
Bid Size 1
Book Value 0.746
City Suzhou
Country China
Crypto Tradeable 0
Currency USD
Current Price 3.8
Current Ratio 3.074
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 3.9977
Day Low 3.73
Debt To Equity 12.068
Display Name Adagene
Earnings Timestamp End 1,753,704,000
Earnings Timestamp Start 1,753,268,340
Ebitda -20,999,432
Ebitda Margins -2.73754
Enterprise To Ebitda -8.198
Enterprise To Revenue 22.442
Enterprise Value 172,150,448
Eps Current Year -0.51
Eps Forward -0.52
Eps Trailing Twelve Months -0.38
Esg Populated 0
Exchange NGM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 3.558
Fifty Day Average Change 0.24199986
Fifty Day Average Change Percent 0.0680157
Fifty Two Week Change Percent 156.75676
Fifty Two Week High 4.75
Fifty Two Week High Change -0.95000005
Fifty Two Week High Change Percent -0.2
Fifty Two Week Low 1.3
Fifty Two Week Low Change 2.5
Fifty Two Week Low Change Percent 1.923077
Fifty Two Week Range 1.3 - 4.75
Financial Currency USD
First Trade Date Milliseconds 1,612,881,000,000
Float Shares 41,416,178
Forward Eps -0.52
Forward P E -7.3076925
Free Cashflow -10,250,600
Full Exchange Name NasdaqGM
Full Time Employees 128
Gmt Off Set Milliseconds -14,400,000
Gross Margins 1.0
Gross Profits 7,670,902
Has Pre Post Market Data 1
Held Percent Insiders 0.11068
Held Percent Institutions 0.20504999
Implied Shares Outstanding 66,072,595
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,021-02-09
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
Long Name Adagene Inc.
Market us_market
Market Cap 251,075,856
Market State PRE
Max Age 86,400
Message Board Id finmb_118162960
Most Recent Quarter 1,767,139,200
Net Income To Common -17,609,412
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 251,075,858
Number Of Analyst Opinions 5
Open 3.89
Operating Cashflow -15,657,450
Operating Margins -0.74959
Payout Ratio 0.0
Phone 86 512 8777 3632
Previous Close 3.89
Price Eps Current Year -7.4509807
Price Hint 4
Price To Book 5.093834
Price To Sales Trailing12 Months 32.73094
Profit Margins -2.29561
Quick Ratio 3.014
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.33333
Region US
Regular Market Change -0.0900002
Regular Market Change Percent -2.31363
Regular Market Day High 3.9977
Regular Market Day Low 3.73
Regular Market Day Range 3.73 - 3.9977
Regular Market Open 3.89
Regular Market Previous Close 3.89
Regular Market Price 3.8
Regular Market Time 1,776,801,601
Regular Market Volume 295,051
Return On Assets -0.15996
Return On Equity -0.34386003
Revenue Growth 73.328
Revenue Per Share 0.163
Sand P52 Week Change 0.3140242
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 66,072,594
Shares Percent Shares Out 0.0015
Shares Short 71,244
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 51,190
Short Name Adagene Inc.
Short Percent Of Float 0.0019
Short Ratio 0.34
Source Interval 15
Symbol ADAG
Target High Price 14.0
Target Low Price 7.0
Target Mean Price 9.4
Target Median Price 8.0
Total Cash 75,844,096
Total Cash Per Share 1.28
Total Debt 6,263,222
Total Revenue 7,670,902
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -0.38
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 2.37944
Two Hundred Day Average Change 1.4205599
Two Hundred Day Average Change Percent 0.59701437
Type Disp Equity
Volume 295,051
Website https://www.adagene.com
Zip 215,123